FDA Grants Traditional Approval to Pirtobrutinib for Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma By Ogkologos - February 4, 2026 316 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the BRUIN-CLL-321 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Breast Cancer Survivor is Swimming the English Channel to Benefit Mental... July 5, 2021 Maximizing the Prospects for Progress Against Cancer June 11, 2018 Empoderar a las personas con cáncer: preguntas y respuestas con la... June 8, 2021 How Early Cancer Detection and Diagnosis Saved My Life Twice: A... December 27, 2023 Load more HOT NEWS Addressing Common Sexual Health Concerns During Cancer Survivorship: An Expert Perspective Foster Teen With A Passion For Painting Is Patiently Waiting For... New on NCI’s Websites for June 2022 FDA Approves Ensartinib for ALK-positive Locally Advanced or Metastatic Non-Small Cell...
